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A b s t r a c t
Background: According to the current guidelines, atrioventricular (DDD) pacing is superior to atrial pacing (AAI) in the treat-
ment of sick sinus syndrome (SSS).
Aim: To compare outcomes of AAI and DDD pacing in patients with SSS during long-term follow-up.
Methods: We studied 809 patients, including 86 patients in the AAI group (57 women, mean age 65 ± 15 years) and 723 pa-
tients in the DDD group (406 women, mean age 71.5 ± 10 years). Evaluation of outcomes of AAI and DDD pacing in SSS 
was based on the analysis of medical records of patients who underwent pacemaker implantation.
Results: Average duration of follow-up was 52 ± 25 months. In the AAI group, 63 of 86 patients remained without inter-
vention. In the DDD group, 661 of 723 patients did not require surgical intervention. Overall, 105 patients died, including 
13 in the AAI group and 92 in the DDD group (p = 0.4516). In the AAI group, a high degree atrioventricular block occurred 
on average after 46.3 ± 8.8 months and its incidence was estimated at 0.85% per year. Atrial fibrillation (AF) developed in 
8 patients in the AAI group and 81 patients in the DDD group (p = 0.23). Among aetiological factors of an increased risk of 
developing AF, only the presence of tachycardia-bradycardia syndrome (hazard ratio [HR] 11.31) and the absence of antiar-
rhythmic therapy (HR 4.23) significantly increased the risk of AF. Urgent reoperation was needed in 23 patients in the AAI 
group and 62 patients in the DDD group (p < 0.01). Log-rank test analysis showed a significant effect of the development 
of AF on the risk of reoperation in this group (p = 0.0420). Lead-related complications were noted in 6 patients in the AAI 
group and 49 patients in the DDD group (p = 0.94). After 45 months, the risk of reoperation in the AAI group increased 
significantly due to a need for ventricular lead implantation.
Conclusions: 1. Atrial stimulation is safe in SSS but it may be associated with an increased risk of ventricular lead implantation 
if atrioventricular block or persistent AF with slow ventricular rate develops. 2. DDD and AAI groups did not differ significantly 
in terms of survival, development of persistent AF, and lead-related complications. 3. Tachycardia-bradycardia syndrome and 
the lack of antiarrhythmic treatment with beta-blocker and amiodarone increased the risk of persistent AF during long-term 
follow-up. 4. A higher rate of reoperations in patients with AAI systems, related mainly to development of persistent AF, es-
pecially after the fourth year of follow-up, may justify DDD system implantation in SSS.
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INTRODUCTION
Sick sinus syndrome (SSS) is defined as a constellation of dis-
turbances leading to inappropriate sinus rhythm rate which 
is too low for current physiologic needs, leading to symptoms 
and/or arrhythmia. Symptomatic treatment includes pacing 
and/or drug therapy. According to the current guidelines, dual 
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chamber pacing (DDD) with preserved native atrioventricular 
(AV) conduction to reduce the risk of atrial fibrillation (AF) and 
stroke, avoid pacing syndrome, and improve quality of life is 
preferred during invasive treatment of SSS (class I A recom-
mendation), and atrial pacing (AAI) is second-line treatment 
(class I B recommendation) [1]. 
AAI pacing does not protect from AV block and slow 
ventricular rate in AF, and thus patients are at risk of the same 
symptoms as in SSS.
Outcomes of AAI and DDD pacing were already com-
pared in the literature but recent reports yielded inconsistent 
results. While Korean and Japanese registries, reported by Kim 
et al. [2] in 2010 and Masumoto et al. [3] in 2004, respectively, 
indicated that AAI pacing is the safest form of therapy in SSS, 
Nielsen et al. [4] in a 2011 report from the Danish DANPACE 
registry preferred DDD pacing as associated with lower rates 
of complications and reoperations (in line with the current 
2013 guidelines) [1].
Thus, although DDD pacing in SSS in recommended in 
the current guidelines, comparisons of DDD and AAI pac-
ing in SSS continue to be warranted in light of the reported 
contradictory results.
The aim of this study was to compare outcomes of AAI and 
DDD pacing in patients with SSS during long-term follow-up.
METHODS
We retrospectively analysed 3,140 patients with an implanted 
pacemaker (PM) who were under care of our centre (all im-
plantations performed during the follow-up period).
The study group included patients following PM implan-
tation due to SSS as documented by 12-lead electrocardio-
graphy (ECG) and/or 24-h Holter ECG monitoring and/or 
treadmill exercise test.
We excluded patients with paroxysmal second/third 
degree AV block, all forms of intraventricular conduction ab-
normalities (including left and right bundle branch block) with 
QRS duration > 120 ms, iatrogenic bradycardia, permanent 
AF and carotid sinus hypersensitivity before the procedure, 
low Wenckebach point ≤ 100 bpm, vascular anomalies, ar-
rhythmias during the procedure, previous cardiac surgery, less 
than 3 follow-up visits, and incomplete pre- or postprocedural 
medical records. Patient groups selected using the above men-
tioned exclusion criteria are shown in Figure 1. Overall, we 
analysed 809 patients with AAI and DDD pacing and reliable 
source data including complete medical records.
Evaluation of outcomes of AAI and DDD pacing in SSS 
was based on the analysis of medical records of patients who 
underwent PM implantation, including records from at least 
3 follow-up visits. 
Figure 1. Patient selection flowchart; AF — atrial fibrillation; AV — atrioventricular; PM — pacemaker; SSS — sick sinus syndrome
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For the purpose of this analysis, we used data from:
 — Preprocedural patient selection sheets;
 — Device implantation protocols from the pacemaker 
IMPULS BIS database run by the Institute of Medical 
Technology and Equipment (ITAM) in Zabrze, Poland;
 — ECGs recorded during the follow-up period;
 — Outpatient records from the electronic patient database;
 — Radiographs and their reports from the digital X-ray Ne-
trad KSS JP2 database;
 — Information about patient deaths from the PESEL data-
base of the Ministry of Interior and Administration.
For patients included into the analysis, we recorded the 
following data:
 — Personal data — gender, age, date of death;
 — Date of implantation/reoperation;
 — Types of pacing complications, their timing, and solutions;
 — History of AF events and other arrhythmia episodes based 
on ECGs and PM mode at subsequent follow-up visits 
(but not based on the mode switch function);
 — Concomitant diseases: hypertension, ischaemic heart 
disease, heart failure, diabetes, thyroid disease;
 — Cardiovascular events;
 — Cerebrovascular events;
 — Information regarding anticoagulants (acenocoumarol, 
warfarin, heparin), antiplatelet drugs (aspirin, clopi-
dogrel), and antiarrhythmic drugs (ajmaline, propafenone, 
mexiletine, sotalol, amiodarone, dronedarone, diltiazem, 
verapamil, beta-blockers) used after implantation.
Primary study endpoints included reoperation, death, 
occurrence of persistent AF, and occurrence of a second or 
third degree AV block.
The diagnosis of permanent AF was made during sub-
sequent follow-up visits when patient rhythm and timing of 
mode switch function activation (pacing mode switch from 
DDD to VVI or DDI) were evaluated.
First follow-up visits were at 1–2 months after the pro-
cedure, followed by 3–6 months after the procedure and 
6–12 months thereafter. Pacing mode, pacing electrical 
parameters (native impulse, pacing threshold, and imped-
ance), and capacity and internal resistance of the battery were 
evaluated by telemetry. 
Twelve-lead ECGs at rest and after application of a magnet 
were performed in all patients.
The study was approved by a local bioethics committee 
(59/KBL/OIL/2012).
Statistical analysis
Quantitative and qualitative data were evaluated using descrip-
tive statistics (range, mean, standard deviation, percentage 
distribution, c2 test or exact Fisher test, Student t test for inde-
pendent samples or Mann-Whitney U test, logistic regression). 
Due to non-normal distribution of quantitative data, 
we used c2 and log-rank tests to evaluate the risk of adverse 
events including reoperation, death, and occurrence of 
permanent AF. Cumulative survival function was interpreted 
graphically using the Kaplan-Meier curve. We used a log-rank 
test to verify the null hypothesis of no significant difference in 
survival between the groups. Then, we used a Cox model to 
analyse potential factors that might affect occurrence of AF. 
We calculated b0, b, odds ratio (OR) and hazard ratio (HR) 
values, and their corresponding 95% confidence intervals.
Results were considered significant when p was less than 
the significance level of a = 0.05. 
Statistical analysis was performed using the Statistica 
10 PL software (StatSoft Poland).
RESULTS
The study group of 809 patients with an implanted PM 
(463 women, 346 men, mean age 70 ± 11 years, range 19– 
–95 years) was selected from 1,355 patients with SSS remain-
ing under the care of our centre, as show in Figure 1. The AAI 
pacing group included 86 patients (57 women, 29 men, mean 
age 65 ± 15 years range 19–81 years), and the DDD pacing 
group included 723 patients (406 women, 317 men, mean 
age 71.5 ± 10 years, range 23–95 years). Minimal duration of 
follow-up was 11 months (with at least 3 follow-up visits during 
this period), maximum duration of follow-up was 101 months, 
and mean duration of follow-up was 52 ± 25 months (AAI 
group: 65 ± 27 months; DDD group: 50 ± 24 months). Patient 
characteristics are shown in Table 1.
During mean 4.3 ± 2.1 years of follow-up, more than 
89.5% of 809 de novo implanted PMs functioned without 
complications or a need for urgent reoperation. No surgical 
intervention was required in 63 (73%) of 86 implanted PMs in 
the AAI group and in 661 (91%) of 723 PMs in the DDD group. 
Overall, 105 (13%) patients died, including 13 (15.1%) in 
the AAI group and 92 (12.7%) in the DDD group (p = 0.4516). 
Mortality in the two groups is shown in Figure 2. The mean 
annual mortality was 2.79% in the AAI group and 3.05% in 
the DDD group (p = 0.53).
In the AAI group (n = 86), AV block occurred in 4 pa-
tients at mean 46.3 ± 8.8 months after PM implantation. 
The risk of AV block was 0.86% per year and was apparent 
in all age groups, as the youngest patient with AV block was 
27 years old, and the oldest was 78 years old (mean age 
55.5 ± 17.3 years). In all these patients, a ventricular lead was 
added. Follow-up evaluations did not include AV conduction 
in patients with DDD systems. Permanent AF developed in 
8 (9.3%) patients in the AAI group and in 81 (11.2%) patients 
in the DDD group (p = 0.2259), as shown in Figure 3. 
Overall, the mean time from PM implantation to devel-
opment of permanent AF was 31.5 ± 22 months (AAI group 
41 ± 33 months, DDD group 31 ± 21 months). Patients with 
tachycardia-bradycardia syndrome developed permanent AF 
at 29.6 ± 20 months, and de novo development of permanent 
AF occurred at 41 ± 29 months (p < 0.01). Annual incidence 
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Table 1. Characteristics of the study patients
Patient characteristics AAI (n = 86) P DDD (n = 723) Overall (n = 809)
Women 57 (66.30%) 0.072 406 (56.15%) 463 (57.23%)
Age 65 ± 15.00 < 0.01 71 ± 10.1 70 ± 11
Tachycardia-bradycardia syndrome 17 (19.77%) < 0.01 374 (51.73%) 391 (48.33%)
Arterial hypertension 61 (70.93%) < 0.01 618 (85.48%) 679 (83.93%)
Ischaemic heart disease 44 (51.16%) 0.049 449 (62.10%) 493 (60.94%)
Diabetes 12 (13.95%) 0.42 126 (17.43%) 138 (17.06%)
Transient ischaemic attack 1 (1.16%) 0.86 10 (1.38%) 11 (1.36%)
Stroke 1 (1.16%) 0.72 12 (1.66%) 13 (1.61%)
Heart failure 9 (10.47%) 0.22 111 (15.35%) 120 (14.83%)
Supraventricular ectopic beats 2 (2.33%) 0.05 59 (8.16%) 61 (7.54%)
Ventricular ectopic beats 4 (4.65%) < 0.01 127 (17.56%) 131 (16.19%)
Myocardial infarction 9 (10.47%) 0.39 100 (13.83%) 109 (13.47%)
Thyroid disease (hyper-/hypothyroidism) 11 (12.79%) 0.72 83 (11.48%) 94 (11.62%)
Drug-induced bradycardia 0 (0.00%) 0.11 21 (2.90%) 21 (2.90%)
Syncope 39 (45.35%) 0.03 417 (57.68%) 456 (56.36%)
MAS attack 20 (23.26%) 0.17 125 (17.29%) 145 (17.92%)
ASA 53 (61.63%) 0.08 373 (51.59%) 426 (52.66%)
Clopidogrel 0 (0.00%) 0.55 3 (0.41%) 3 (0.37%)
ASA + clopidogrel 1 (1.16%) 0.75 6 (0.83%) 7 (0.86%)
Acenocoumarol 7 (8.14%) < 0.01 185 (25.59%) 192 (23.73%)
LMWH 2 (2.33%) 0.36 32 (4.43%) 34 (4.20%)
Beta-blocker 35 (40.69%) 0.03 470 (65.00%) 505 (62.42%)
Antiarrhythmic drugs (class I, III, IV) 14 (16.27%) < 0.01 320 (44.26%) 334 (41.28%)
Other antiarrhythmic drugs 10 (11.62%) < 0.01 301 (41.63%) 311 (38.44%)
ASA — acetylsalicylic acid; LMWH — low molecular weight heparin; MAS — Morgagni-Adams-Stokes
Figure 2. Survival after pacemaker implantation (DDD/AAI) Figure 3. Survival free from atrial fibrillation in both study 
groups (AAI/DDD)
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of AF was 1.72% in the AAI group and 2.7% in the DDD 
group. Patients in the DDD group with right ventricular apex 
(RVA) lead developed permanent AF at a rate of 3.33% per 
year vs. 2.5% per year in those with right ventricular outflow 
tract (RVOT) lead (p = 0.317). Unfortunately, due to a retro-
spective nature of our study we were unable to evaluate the 
percentage of ventricular pacing in the DDD group.
When we evaluated the presence of a first degree AV 
block, which was not an exclusion criterion for the DDD group 
(n = 723), a Cox proportional hazard model indicated that 
the development of a first degree AV block had no significant 
effect (p = 0.3016) on the time to AF occurrence. 
Antiarrhythmic drug therapy is a factor protecting from 
the development of permanent AF. In monotherapy, best 
outcomes were noted for bisoprolol (p < 0.01) but the best 
protection from the development of permanent AF was af-
Figure 4. Predictors of atrial fibrillation — hazard ratios with 95% confidence intervals (CI) and p values; ACS — acute coronary 
syndrome; IHD — ischaemic heart disease; SVEB/SVT — supraventricular ectopic beats/supraventricular tachycardia;  
TB/PAF — tachycardia-bradycardia syndrome/paroxysmal atrial fibrillation
Table 2. Cox model results for tachycardia-bradycardia syndrome 
as a predictor of atrial fibrillation after pacemaker implantation
Beta 2.4258
Standard error 0.3958
Beta lower 95% confidence limit 1.6499
Beta upper 95% confidence limit 3.2016
T 6.1282
Wald statistic 37.5546
P 0.00
Hazard ratio (HR) 11.3110
HR lower 95% confidence limit 5.2067
HR upper 95% confidence limit 24.5719
Table 3. Cox model results for lack of antiarrhythmic treatment 
as a predictor of atrial fibrillation after pacemaker implantation
Beta 1.472
Standard error 0.5129
Beta lower 95% confidence limit 2.477
Beta upper 95% confidence limit 0.466
T 2.869
Wald statistic 8.2368
P 0.00
Hazard ratio (HR) 4.2345
HR lower 95% confidence limit 2.2334
HR upper 95% confidence limit 6.4325
forded by a combination of a long-acting beta-blocker and 
amiodarone (p < 0.01) which significantly prolonged the time 
from PM implantation to development of AF. Other upstream 
treatment was not analysed.
Among eatiological factors of an increased risk of devel-
oping permanent AF (age, gender, tachycardia-bradycardia 
syndrome, supraventricular extrasystoles, lack of antiar-
rhythmic treatment, thyroid disease, ischaemic heart disease, 
hypertensive heart disease, heart failure, first degree AV block), 
only the presence of tachycardia-bradycardia syndrome (HR 
11.31) and the absence of antiarrhythmic therapy (HR 4.23) 
was shown to significantly increase the risk of AF. Predictors of 
an increased risk of AF development are shown in Figure 4 and 
in Tables 2 and 3.
In the AAI group, reoperation was performed in 23 (26.7%) 
patients compared to 62 (8.57%) patients in the DDD group 
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(p < 0.01). Time to reoperation differed significantly differed 
significantly between the DDD and AAI groups (p = 0.0338, 
log-rank test). In the DDD group, the likelihood of survival 
without reoperation remained constant, while it decreased 
with time in the AAI group. This was particularly seen after 
45 months, when the risk of reoperation in the AAI group rose 
sharply due to the need of ventricular lead insertion. The likeli-
hood of survival free from reoperation is shown in Figure 5.
Surgical change of the mode of pacing from AAI to VVI 
due to permanent AF was performed in 13 (15%) patients, 
and from DDD to VVI in 1 (0.14%) patient (p < 0.01). The 
mean time from PM implantation to surgical change in the 
mode of pacing was 46.7 ± 25.2 months. In the remaining 
47 cases when mode of pacing had to be switched from DDD 
to VVI(R), this was performed using a remote programming 
device and reoperation was not necessary.
In the AAI group, the need to insert a ventricular lead 
due to development of AF leading to clinical symptoms of 
bradycardia (pauses > 3 s, minimal heart rate < 30 bpm, 
dizziness) occurred at a rate of 1.72% per year. Log-rank test 
analysis showed a significant effect of the development of 
AF on the risk of reoperation in this group (p = 0.0420). The 
likelihood of survival free from reoperation and development 
of permanent AF in the AAI group is shown in Figure 6.
Lead-related complications (lead displacement, lead 
damage, exit block) were noted in 6 (6.9%) patients in the AAI 
group and in 49 (6.7%) patients in the DDD group (p = 0.94). 
Overall, complications were more frequent in the AAI group 
than in the DDD group (26.7% vs. 8.57%, p < 0.01), as 
shown in Table 4.
DISCUSSION
Many reports have been published in the literature regarding 
the effectiveness of pacing therapy in SSS, rates and types of 
complications, and mortality after PM implantation. These 
were often multicentre analyses leading to new management 
algorithms and new guidelines, and sometimes only summa-
ries of alternative approaches to pacing in SSS [2–8]. Until 
now, no other study summarised such a long-term patient 
follow-up, mean 4.3 years (with the longest follow-up duration 
of 8 years), in the invasive treatment of SSS, comparing the 
effectiveness of AAI and DDD pacing. We were also motivated 
to perform this comparison due to the fact that atrial pacing 
systems are currently implanted in a small minority of patients 
with SSS and are not considered treatment of choice. Thus, 
we wanted to reevaluate the usefulness of AAI pacing in SSS 
based on our own experience.
Since 1997, after the era of comparisons of single cham-
ber atrial (AAI) vs. single chamber ventricular (VVI) pacing, 
AAI pacing became to be compared in the literature with dual 
chamber pacing (DDD) which started to be more commonly 
used. Initial comparative studies showed superiority of AAI 
pacing as a more physiologic approach preserving native AV 
conduction [5, 6] in patients with SSS. This was confirmed in 
the studies by Moríñigo et al. [7], Masumoto et al. [3], Tripp 
et al. [8], and Kim et al. [2], until results of the Danish DAN-
PACE registry were reported in 2011 [4], overturning previous 
beliefs about superiority of AAI pacing. The latter was shown 
not to protect from bradycardia due to AV block or AF with 
slow ventricular rate, putting patients at an increased risk of 
reoperation. 
Figure 5. Survival free from reoperation in both study groups 
(AAI/DDD)
Figure 6. Survival free from reoperation and development of 
permanent atrial fibrillation (AF) in the AAI group
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Despite many multicentre trials published during the 
last 15 years, many questions remain unanswered. It is still 
not clear what the long-term clinical effectiveness of DDD 
and AAI pacing is in the Polish population of patients with 
SSS. Specifically, it is not known whether complication rates, 
mortality and the development of AF are similar in patients 
treated with these two pacing modes.
Atrioventricular block
The development of a high-degree AV block must be consid-
ered when comparing advantages and disadvantages of AAI 
and DDD pacing in patients with SSS. In our study, 4 patients 
in the AAI group required implantation of an additional ven-
tricular lead due to development of a symptomatic second 
degree AV block. The rata of the latter was calculated at 
0.85% per year and is comparable to the rates reported in 
the literature [9, 10]. Of note, none of our patients developed 
significant bradycardia that would require urgent surgical 
intervention. Timing of conversion from AAI to DDD pacing 
is still a matter of debate. Rosenqvist et al. [11] highlighted 
that asymptomatic episodes of a high-degree AV block may 
reflect changes in the autonomic nervous system and not de-
generative changes in the AV node itself, as evidenced by an 
intermittent nature of the block, occurring mostly during the 
night. In addition, the most common cause of AV conduction 
disturbances is drug therapy and not degenerative changes in 
the cardiac conduction system [12].
Atrial fibrillation
Atrial fibrillation is one of long-term complications of sinus 
node dysfunction. Historically, in regard to the development of 
AF, comparisons of AAI and DDD pacing were always favour-
ing the former, starting from the 2003 study by Moriñigo et 
al. [7] in 177 patients (with AF developing in 7.4% patients in 
the AAI group and 23% patients in the DDD group), through 
the studies by Masumoto et al. [3] (AF in 4.2% patients in 
the AAI group and 8% patients in the DDD group) and Tripp 
et al. [8] (AF in 2.8% patients in the AAI group and 15.2% 
patients in the DDD group), until the DANPACE study in 
2011 showed for the first time that the proportion of patients 
developing AF was higher in the AAI group than in the DDD 
group (28.4% vs. 23%, respectively). In the latter study, more 
frequent occurrence of AF in the AAI group was thought to be 
due to a prolonged AV conduction time with pacing from the 
right atrial appendage. In this scenario, ventricular preload is 
reduced, increasing diastolic backward flow through the mitral 
valve and thus leading to an increased risk of AF. It was shown 
that the rate of AF increases when the PR interval is > 180 ms 
[13]. In our study population, overall rate of permanent AF 
was 11% (9.3% in the AAI group and 11.2% in the DDD 
group), with no significant difference between the two groups 
by log-rank test. The mean time to the development of AF 
was 31.5 ± 22 months and was notably shorter in patients 
with tachycardia-bradycardia syndrome (29.6 ± 20 months) 
than in patients developing AF de novo (41 ± 29 months). 
In addition, tachycardia-bradycardia syndrome was shown 
to be a significant predictor of the development of AF. In our 
study, we did not consider the rate of ventricular pacing due 
to a retrospective nature of this analysis. To evaluate the rate 
of AF in the AAI group, our results may be compared with 
the results of a 5.4-year follow-up of patients with AAI pacing 
systems reported by Moriñigo et al. [7]. The latter study was 
performed in a similar patient population in regard to the 
mean age, gender, and concomitant diseases. The rate of AF 
was 10%, and thus it was comparable to the rate reported in 
the present study.
Table 4. Summary of complications of cardiac electrotherapy and the need for reoperation
Complications AAI DDD P Overall Not requiring 
reoperation
Lead displacement 3 (3.49%) 23 (3.18%) 0.88 26 (3.21%) 0
Lead damage 1 (1.16%) 6 (0.83%) 0.75 7 (0.87%) 1
Exit block 2(2.33%) 14 (1.94%) 0.80 16 (1.98%) 3
Change of pacing mode 13 (15.12%) 1 (0.14%) < 0.01 14 (1.73%) 0
Inappropriate pacemaker function 0 (0%) 2 (0.28%) 0.62 2 (0.25%) 0
Pneumothorax 1 (1.16%) 3 (0.41%) 0.35 4 (0.49%) 0
Pocket hematoma 2 (2.33%) 2 (0.28%) 0.01 4 (0.49%) 0
Muscle stimulation 0 (0%) 3 (0.41%) 0.55 3 (0.37%) 1
Pocket mechanical trauma 1 (1.16%) 2 (0.28%) 0.20 3 (0.37%) 0
Myocardial perforation 0 (0%) 3 (0.41%) 0.55 3 (0.37%) 0
Venous occlusion 0 (0%) 2 (0.28%) 0.62 2 (0.25%) 1
Pocket infection 0 (0%) 1 (0.14%) 0.73 1 (0.12%) 0
Overall 23 (26.7%) 62 (8.57%) < 0.01 85 (10.5%) 6
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Is the development of AF an absolute indication for im-
plantation of an additional lead in AAI systems? The study by 
Masumoto et al. [3] showed that even in patients with AAI 
systems who developed chronic AF, it was not necessary to 
implant an additional ventricular lead to treat bradycardia. 
Andersen et al. [14] also arrived at similar conclusions. In our 
study group, AF with symptomatic bradycardia was one of the 
major causes of reoperation in the AAI group and change of 
the pacing mode in the DDD group. Perhaps our approach 
was too cautious as none of the studied patients developed 
full-blown syncope despite significant bradycardia. Practice 
indicates that decisions to implant a PM in permanent AF are 
very often arbitrary and this treatment may be overused. As 
reoperation is performed in about 15% of patients with an AAI 
system, these decisions have a significant effect on the results 
of clinical observations. On the other hand, these decisions 
reflect everyday clinical practice.
Selected factors predisposing  
to the development of AF
In a Cox model, among potential factors affecting develop-
ment of permanent AF (ventricular lead location, presence 
of tachycardia-bradycardia syndrome, first degree AV block, 
concomitant thyroid disease, supraventricular extrasystoles, 
ischaemic heart disease, hypertensive heart disease, heart 
failure, lack of antiarrhythmic treatment), only the presence of 
tachycardia-bradycardia syndrome and lack of antiarrhythmic 
treatment after PM implantation were shown to be significant 
predictors of AF. The best combination of antiarrhythmic 
drugs offering protection from AF was that of a beta-blocker 
and amiodarone.
The above mentioned tachycardia-bradycardia syn-
drome, i.e. paroxysmal AF preceded by sinus bradycardia, 
was the most significant factor affecting the development of 
permanent AF, more important that the lack of AV synchrony 
in a third degree AV block [15].
In our study, we were unable to confirm an effect of 
a first degree AV block (PR interval 200 ms) on the rate of 
AF. In contrast, the DANPACE study showed that the PR 
interval ≥ 180 ms predisposed to the development of AF 
[13]. Thus, DDD pacing protects patients from the devel-
opment of AF. In our earlier observations, we showed that 
abrupt prolongation of the PR interval occurred at the age 
of 61–70 years, mostly in those patients in whom the mean 
preimplantation PR interval was 196 ms [16]. Those patients 
were at an increased risk of AF development and reoperation. 
In the current analysis, likely due to a low number of patients 
in the AAI group (n = 86), we were unable to confirm the 
results of DANPACE study. Similarly, ventricular lead loca-
tion (RVOT vs. RVA, p = 0.317) and age (p = 0.078) had 
no significant effect on the development of AF, although the 
mean age of patients with AF was more than 2 years higher 
compared to patients without AF [17, 18]. In our opinion, this 
may be attributed to the selection of patients. In the study 
by Majewski et al. [19], evaluating durability of DDD pacing, 
3 factors were shown to significantly affect AF development, 
including SSS, tachycardia-bradycardia syndrome and age. 
Of note, however, the mean patient age in that analysis was 
more than 5 years lower that in the present study. 
Selected lead-related complications
Damage of an intracardiac lead is one of the most important 
complications during long-term follow-up after PM implan-
tation. The relative risk of lead damage and failure to pace 
with DDD systems is estimated to be increased 2.045 times 
compared to AAI pacing, due to a twice higher number of 
implanted pacing leads. Hauser et al. [20] noted a 6% rate 
of ventricular lead damage during 5 years of dual chamber 
pacing. Helguera et al. [21] concluded that in older patients 
(> 65 years), atrial leads were characterised by a much lower 
rate of verified malfunctions. The number of indwelling leads 
is also important. Each reoperation is associated with an ap-
proximately 2% risk of infection, and the latter is an indica-
tion for complete pacing system removal [22]. In our study 
population, lead-related complications were among the most 
common causes for reoperation but unlike other authors, we 
did not find a difference in their rate depending on pacing 
mode (7% in the AAI group vs. 6% in the DDD group). This 
observation is in favour of DDD pacing and does not support 
the conclusion that DDD pacing is associated with a twice 
higher rate of lead-related complications, as these are mostly 
related to atrial leads (88.46% of all lead-related complica-
tions). Obviously, we are aware that the number of implanted 
AAI systems (n = 86) was relatively small. The rate of other 
complication is comparable to that reported in other centres, 
ranging from 10.1% [23] to 12.4% [24].
Limitations of the study
Our study was a nonrandomised, retrospective, single-centre 
observation that included a relatively low number of patients 
with atrial pacing. The results might have also been affected by 
the inclusion/exclusion criteria used in our study, specifically 
the need for complete procedural and long-term follow-up 
records for a patient to be included in the analysis.
Summary
During mean 4.3 years of follow-up of 809 patients with 
a de novo implanted PM, more than 89.5% of these devices 
functioned without complications or the need for reopera-
tion. We did not show significant differences between the 
DDD and AAI groups in terms of survival, development of 
persistent AF, and lead-related complications although the 
two groups differed in age (by about 6 years) and the severity 
of concomitant conditions. Specifically, patients in the DDD 
group were older and more often had tachycardia-bradycardia 
syndrome, ventricular ectopy, paroxysmal supraventricular 
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arrhythmias, heart failure, ischaemic heart disease, diabetes, 
and arterial hypertension. Beyond 4 years of use, the AAI 
system becomes unstable (with a significant increase in the 
reoperation rate) and thus the proportion of AAI systems 
without the need for intervention is smaller (73%) compared 
to DDD systems (91%).
In summary, our observations favour DDD and not AAI 
pacing in the treatment of SSS. These findings are in agree-
ment with the current 2013 recommendations on the choice 
of pacing mode in patients with dysfunction of sinus node 
automaticity [1].
CONCLUSIONS
1. Atrial stimulation is safe in SSS but associated with an 
increased risk of ventricular lead implantation due to 
development of AV block or persistent AF with AV con-
duction disturbances.
2. DDD and AAI groups did not differ significantly in terms 
of survival, development of persistent AF, and lead-relat-
ed complications.
3. Tachycardia-bradycardia syndrome and the lack of antiar-
rhythmic treatment were associated with an increased risk 
of persistent AF during long-term follow-up.
4. Due to a higher rate of reoperations in patients with AAI 
systems, related mainly to development of persistent AF, 
especially after the fourth year of follow-up, DDD system 
implantation in SSS may be of more benefit.
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S t r e s z c z e n i e
Wstęp: Zespół chorego węzła zatokowego (SSS) to zespół zaburzeń powodujących nieprawidłową częstotliwość rytmu zatokowego, 
zbyt wolną do bieżących potrzeb fizjologicznych, co prowadzi do wystąpienia objawów klinicznych lub arytmii. Zgodnie z najnow-
szymi wytycznymi w leczeniu SSS bez zaburzeń przewodzenia przedsionkowo-komorowego (AV), preferuje się stymulację AV (DDD) 
względem stymulacji przedsionkowej (AAI).
Cel: Celem pracy było porównanie wyników leczenia chorych z wdrożoną stymulacją AAI lub DDD z powodu SSS w obserwacji odległej.
Metody: Łącznie grupa badana liczyła 809 osób (463 kobiety, 346 mężczyzn, wiek: 19–95 lat, średnio: 70 ± 11 lat). Grupa AAI 
obejmowała 86 chorych (57 kobiet, 29 mężczyzn, wiek: 19–81 lat, średnio: 65 ± 15 lat) a grupa DDD 723 pacjentów (406 kobiet, 
317 mężczyzn, wiek: 23–95 lat, średnio: 71,5 ± 10 lat). Badanie skuteczności stymulacji AAI i DDD w SSS odbyło się na podstawie 
analizy dokumentacji medycznej chorych poddanych implantacji stymulatora i dokumentacji z co najmniej 3 wizyt kontrolnych. 
Pierwszorzędowymi punktami końcowymi obserwacji były: reoperacja, zgon, migotanie przedsionków (AF), blok AV. 
Wyniki: Średni czas obserwacji wynosił 52 ± 25 miesięcy (AAI: 65 ± 27; DDD: 50 ± 24). W grupie AAI na 86 wszczepionych 
rozruszników 63 (73%) pozostało bez interwencji. W grupie DDD na 723 wszczepionych rozruszników 661 (91%) urządzeń nie 
wymagało interwencji chirurgicznej. W obu grupach badanych zmarło łącznie 105 osób (13%) — 13 z grupy AAI (15,1%) i 92 (12,7%) 
z grupy DDD (p = 0,4516). Blok AV w grupie badanej występował średnio po 46,3 ± 8,8 miesiącu po wszczepieniu stymulatora AAI. 
Rozwój utrwalonego AF zanotowano u 8 (9,3%) chorych z grupy AAI i u 81 (11,2%) osób z grupy DDD (p = 0,23). Wykazano, że 
wystąpieniu AF sprzyjają: obecność zespołu tachykardia–bradykardia (HR = 11,31) i brak skojarzonego leczenia antyarytmicznego 
(beta-adrenolitykiem i amiodaronem) (HR = 4,23). Reoperacja dotyczyła 23 (26,7%) osób z grupy AAI i 62 (8,57%) pacjentów z grupy 
DDD (p < 0,01). Operacyjną zmianę trybu stymulacji z AAI na VVI z powodu utrwalonego AF wykonano u 13 (15%) osób, a z DDD 
na VVI u 1 (0,14%) chorego (p < 0,01). W pozostałych 47 przypadkach rozwoju AF w grupie DDD tryb zmieniano za pomocą pro-
gramatora. Ryzyko konieczności doszczepienia elektrody komorowej z powodu AF kształtowało się na poziomie 1,72%/rok w grupie 
badanej AAI. Analiza testu log-rank wykazała istotność wypływu rozwoju AF na reoperację w tej grupie chorych (p = 0,0420). Po-
wikłania związane z elektrodami zarejestrowano w grupie AAI u 6 (6,9%) osób, a w grupie DDD u 49 (6,7%) pacjentów (p = 0,94). 
Czasy do reoperacji różnią się istotnie wśród osób, które mają wszczepiony rozrusznik typu DDD, a tymi, którym implantowano 
urządzenie typu AAI (p = 0,0338; test log-rank). Po 45 miesiącach ryzyko wystąpienia reoperacji w grupie AAI gwałtownie wzrasta 
i jest spowodowane koniecznością doszczepienia elektrody komorowej.
Wnioski: 1. Stymulacja przedsionkowa jest bezpieczna w SSS, jednak wiąże się z podwyższonym ryzykiem konieczności doszcze-
pienia elektrody komorowej z powodu bloku AV lub rozwoju utrwalonego AF z zaburzeniami przewodzenia AV. 2. Między grupami 
DDD i AAI nie wykazano statystycznie istotnych różnic dotyczących czasu przeżycia, rozwoju utrwalonego AF, powikłań związanych 
z elektrodami. 3. Obecność zespołu tachykardia–bradykardia i brak leczenia antyarytmicznego wiążą się z ryzykiem rozwoju utrwa-
lonego AF w obserwacji odległej. 4. Ze względu na większy odsetek reoperacji u chorych ze stymulacją AAI, wynikających głównie 
z rozwoju utrwalonego AF z bradykardią, zwłaszcza po 4. roku obserwacji, stosowanie układów DDD w SSS może być korzystniejsze.
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